Keytarzi 150mg Irbesartan Tablets | Amros Pharmaceuticals

Description

Keytarzi 150mg Tablets contain Irbesartan, a prescription antihypertensive medicine belonging to the angiotensin II receptor blocker (ARB) class.

Irbesartan blocks the effects of angiotensin II, allowing blood vessels to relax and reducing peripheral vascular resistance.

The 150mg strength is the usual recommended adult starting dose for hypertension under U.S. prescribing information.

Irbesartan is also indicated for diabetic nephropathy in hypertensive patients with type 2 diabetes, elevated serum creatinine and proteinuria. However, the recommended reference dose for this indication is 300mg once daily.

Effective hypertension management helps reduce the risk of cardiovascular complications, including stroke and myocardial infarction.

Therapeutic Indications

• Treatment of hypertension.

• Irbesartan treatment for diabetic nephropathy in selected patients with type 2 diabetes, hypertension, elevated serum creatinine and proteinuria, at the appropriate prescribed dosage.

Dosage & Administration

The usual adult reference starting dose for hypertension is 150mg once daily. The dose may be increased to 300mg daily according to blood pressure response.

For diabetic nephropathy, the reference recommended dose is 300mg once daily.

Irbesartan may be taken with or without food. Treatment must follow the prescribing physician’s instructions.

Possible Side Effects

Dizziness, orthostatic dizziness, low blood pressure, and increased potassium levels. Kidney function changes may occur.

Contraindications & Precautions

Avoid use during pregnancy because of fetal toxicity. Do not use in patients with known hypersensitivity or together with aliskiren in patients with diabetes.

Patients with dehydration, kidney impairment, or elevated potassium may require closer monitoring.

NSAIDs may reduce the antihypertensive effect and increase kidney-related risks. Concurrent lithium may increase the risk of lithium toxicity.